A new study investigated vaccine efficacy of a primary series and booster dose across multiple variants, including the BA.1 omicron variant, in SLE patients. This is one of the first studies on vaccine efficacy of a primary series and booster dose across multiple variants, including the BA.1 omicron variant, especially in an autoimmune disease patient cohort.
Read More »A peer-reviewed case report published yesterday in the journal Cureus discusses the first documented case of a reactivation of autoimmune hepatitis in remission following the administration of a COVID-19 vaccine. Nine previously published case studies have also reported cases of autoimmune hepatitis being diagnosed after the administration of a COVID-19 vaccine.
Read More »In a research article published yesterday in Frontiers in Oncology, COVID-19 vaccine (Pfizer and Moderna) safety was evaluated in a population of 566 immunocompromised patients including those with hematological malignancies (131), solid tumors (191), immune-rheumatological diseases (86), and neurological disease (158) including multiple sclerosis and generalized myasthenia.
Read More »A recent study evaluated the safety and efficacy of the Moderna, Pfizer, and Johnson & Johnson COVID-19 vaccines in dermatomyositis (DM) patients compared to non-DM patients at 1, 30, and 60 days post-vaccination. At 60 days post-vaccination, the DM group was observed to be at greater risk for adverse events of special interest compared to controls, albeit very small (absolute risk was .6%). No differences were observed for breakthrough infection or all-cause hospitalization at 60 days post-vaccination.
Read More »